Financial Survey: Polydex Pharmaceuticals (OTCMKTS:POLXF) and BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Polydex Pharmaceuticals (OTCMKTS:POLXF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Polydex Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84 million	2.69	$263.86 million	$1.20	7.82
Polydex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

BioCryst Pharmaceuticals has higher revenue and earnings than Polydex Pharmaceuticals.

Insider & Institutional Ownership

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 12.9% of Polydex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BioCryst Pharmaceuticals and Polydex Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	30.16%	-84.33%	61.35%
Polydex Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and target prices for BioCryst Pharmaceuticals and Polydex Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0	3	10	0	2.77
Polydex Pharmaceuticals	0	0	0	0	0.00

BioCryst Pharmaceuticals presently has a consensus target price of $19.64, suggesting a potential upside of 109.34%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe BioCryst Pharmaceuticals is more favorable than Polydex Pharmaceuticals.

Summary

BioCryst Pharmaceuticals beats Polydex Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

About Polydex Pharmaceuticals

Polydex Pharmaceuticals Ltd. is a development stage company, which engages in manufacturing of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry, and the development, manufacturing, and marketing of biotechnology-based products for the human pharmaceutical market. The firm focuses on Dextran and derivative products, including Iron Dextran and Dextran Sulphate and other specialty chemicals. The company was founded by Thomas C. Usher on June 14, 1979 and is headquartered in Toronto, Canada.